Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Abstract
Dickkopf-1 (DKK1) modulates Wnt signaling, promoting tumor growth, metastasis, and immunosuppression. High DKK1 expression has been detected in various tumor types—including biliary tract cancer (BTC)—and is associated with poor prognosis. DKN-01—a humanized mAb targeting DKK1—was evaluated in a phase I multicenter study in combination with gemcitabine and cisplatin in patients with unresectable or metastatic BTC with no prior systemic therapy for advanced disease.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1310
Entities
People
- Alok A. Khorana
- Andrew X Zhu
- Anthony B. El-khoueiry
- Cynthia Sirard
- Dan G Duda
- Devalingam Mahalingam
- Gulam A. Manji
- Jennifer R. Eads
- Lipika Goyal
- Michael H. Kagey
- Michael Schrag
- Rebecca Miksad
- Stacey Stein
- Thomas A Abrams
Organizations
- Georgetown University Medical Center
- Harvard Medical School
- Massachusetts General Hospital
- United States Department of Defense
- University of Pennsylvania
- University of Southern California